Short answer
ACTUATE THERAPEUTICS, INC. (ACTU) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$3M
- +36.7% YoY · +29.7% QoQ
- EPS (diluted)
- −$0.14
- +44.0% YoY · +30.0% QoQ
Source: XBRL data from the ACTUATE THERAPEUTICS, INC. (ACTU) Q3 2026 10-Q on SEC EDGAR. USD.
ACTUATE THERAPEUTICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales generated
- Operating margin not applicable, operating loss $3,439,087 vs $5,472,378 YoY
- Worst expense category: R&D $1,811,601 vs $2,177,922, down $366,321
- Cash $2,101,816; operating cash use $12,373,256 for nine months
- October offering net proceeds $11,764,494; substantial doubt regarding going-concern status and additional funding needs
Risk Factors
- No material changes identified in the 10-Q Risk Factors section versus the 2025 10-K
- Liquidity risk: cash $2,101,816 and working-capital deficit $974,694, with substantial doubt about going-concern status
- Capital-markets risk: funding needs persist despite $11,764,494 October offering net proceeds
- Nasdaq compliance risk: noncompliance with $50 million MVLS and $1.00 minimum-bid requirements
- Clinical-development risk: elraglusib advancement depends on FDA or EMA feedback and patient enrollment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACTUATE THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.